Modified natural nanoparticles as contrast agents for medical imaging

Advanced Drug Delivery Reviews

Volumn 62, Issue 3, 2010, Pages 329-338

  Cormode, David P ^a   Jarzyna, Peter A ^a   Mulder, Willem J M ^a   Fayad, Zahi A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast agents; Lipoproteins; Medical imaging; MRI; Nanoparticles; Viruses

Indexed keywords

CONTRAST AGENT; CONTRAST AGENTS; EFFECTIVE CONTRAST AGENTS; FLUORESCENCE TECHNIQUE; GOLD NANOPARTICLES; INORGANIC NANOPARTICLE; LIPOPROTEINS; NANOPARTICLE CONTRAST AGENT; NATURAL TARGETS; ON-GOING IMPROVEMENT; QUANTUM DOT; SMALL MOLECULES; TARGETING MOLECULES;

BIODEGRADATION; FLUOROPHORES; GADOLINIUM; IRON OXIDES; LIPIDS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; POSITRON EMISSION TOMOGRAPHY; PROTEINS; RESONANCE; SEMICONDUCTOR QUANTUM DOTS; VIRUSES;

MEDICAL IMAGING;

CONTRAST MEDIUM; FERRITIN; FLUORINE; FLUOROBENZALDEHYDE F 18; GADOLINIUM; GADOTERIC ACID; GREEN FLUORESCENT PROTEIN; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; NANOCRYSTAL; NANOPARTICLE; QUANTUM DOT; TECHNETIUM; THULIUM; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VIRUS DNA; VIRUS RNA;

BACTERIOPHAGE; CHEMICAL MODIFICATION; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL MICROSCOPY; COWPEA CHLOROTIC MOTTLE VIRUS; DRUG ACCUMULATION; DRUG DISTRIBUTION; HUMAN; IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TRANSMISSION ELECTRON MICROSCOPY; VIRUS; VIRUS CAPSID;

ANIMALS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; FERRITINS; HUMANS; LIPOPROTEINS; NANOPARTICLES; NANOTECHNOLOGY; VIRUSES;

EID: 76749138879     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.11.005     Document Type: Review

References (109)

1. Lauterbur P.C. Image formation by induced local interactions: examples employing nuclear magnetic resonance. Nature 242 (1973) 190-191
2. Hounsfield G.N. Computerized transverse axial scanning (tomography): Part I. Description of system. Br. J. Radiol. 46 (1973) 1016-1022
3. Basser P.J., Mattiello J., and LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys. J. 66 (1994) 259-267
4. Rudd J.H.F., Warburton E.A., Fryer T.D., Jones H.A., Clark J.C., Antoun N., Johnstrom P., Davenport A.P., Kirkpatrick P.J., Arch B.N., Pickard J.D., and Weissberg P.L. Imaging atherosclerotic plaque inflammation with [F-18]-fluorodeoxyglucose positron emission tomography. Circulation 105 (2002) 2708-2711
5. Padhani A.R. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J. Magn. Reson. Imaging 16 (2002) 407-422
6. Calcagno C., Cornily J.-C., Hyafil F., Rudd J.H.F., Briley-Saebo K.C., Mani V., Goldschlager G., Machac J., Fuster V., and Fayad Z.A. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1311-1317
7. Mulder W.J.M., Griffioen A.W., Strijkers G.J., Cormode D.P., Nicolay K., and Fayad Z.A. Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine 2 (2007) 307-324
8. Corot C., Robert P., Idee J.-M., and Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 58 (2006) 1471-1504
9. Azzazy H.M.E., Mansour M.M.H., and Kazmierczak S.C. From diagnostics to therapy: prospects of quantum dots. Clin. Biochem. 40 (2007) 917-927
10. Huang X., El-Sayed I.H., Qian W., and El-Sayed M.A. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Am. Chem. Soc. 128 (2006) 2115-2120
11. Bulte J.W.M., and Kraitchman D.L. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 17 (2004) 484-499
12. Smith A.M., Duan H., Mohs A.M., and Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev. 60 (2008) 1226-1240
13. D.P. Cormode, T. Skajaa, Z.A. Fayad, W.J.M. Mulder, Nanotechnology in medical imaging: probe design and applications, Arterioscler. Thromb. Vasc. Biol. 29 (2009) 992-1000.
14. Mulder W.J.M., Strijkers G.J., van Tilborg G.A.F., Griffioen A.W., and Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 19 (2006) 142-164
15. McCarthy J.R., Kelly K.A., Sun E.Y., and Weissleder R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine 2 (2007) 153-167
16. Medintz I.L., Uyeda H.T., Goldman E.R., and Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater. 4 (2005) 435-446
17. Kim D., Park S., Lee J.H., Jeong Y.Y., and Jon S. Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo x-ray computed tomography imaging. J. Am. Chem. Soc. 129 (2007) 7661-7665
18. Cormode D.P., Skajaa T., van Schooneveld M.M., Koole R., Jarzyna P., Lobatto M.E., Calcagno C., Barazza A., Gordon R.E., Zanzonico P., Fisher E.A., Fayad Z.A., and Mulder W.J.M. Nanocrystal core high-density lipoproteins: a multimodal molecular imaging contrast agent platform. Nano Lett. 8 (2008) 3715-3723
19. Rabin O., Perez J.M., Grimm J., Wojtkiewicz G., and Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat. Mater. 5 (2006) 118-122
20. Hyafil F., Cornily J.C., Feig J.E., Gordon R., Vucic E., Amirbekian V., Fisher E.A., Fuster V., Feldman L.J., and Fayad Z.A. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 13 (2007) 636-641
21. Mukundan S., Ghaghada K.B., Badea C.T., Kao C.-Y., Hedlund L.W., Provanzale J.M., Johnson G.A., Chen E., Bellamkonda R.V., and Annapragada A. A liposomal nanoscale contrast agent for preclinical CT in mice. Am. J. Roentgenol. 186 (2006) 300-307
22. Amirbekian V., Lipinski M.J., Briley-Saebo K.C., Amirbekian S., Aguinaldo J.G., Weinreb D.B., Vucic E., Frias J.C., Hyafil F., Mani V., Fisher E.A., and Fayad Z.A. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 961-966
23. Mulder W.J.M., Strijkers G.J., Griffioen A.W., van Bloois L., Molema G., Storm G., Koning G.A., and Nicolay K. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug. Chem. 15 (2004) 799-806
24. Lanza G.M., Winter P.M., Caruthers S.D., Hughes M.S., Cyrus T., Marsh J.N., Neubauer A.M., Partlow K.C., and Wickline S.A. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine 1 (2006) 321-329
25. van Schooneveld M.M., Vucic E., Koole R., Zhou Y., Stocks J., Cormode D.P., Tang C.Y., Gordon R., Nicolay K., Meijerink A., Fayad Z.A., and Mulder W.J.M. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett. 8 (2008) 2517-2525
26. Sitharaman B., Kissell K.R., Hartman K.B., Tran L.A., Baikalov A., Rusakova I., Sun Y., Khant H.A., Ludtke S.J., Chiu W., Laus S., Toth W., Helm L., and Merbach A.E. Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem. Commun. (2005) 3915-3917
27. Klibanov A.L., Maruyama K., Torchilin V.P., and Huang L. Amphipatic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268 (1990) 235-238
28. Mulder W.J.M., Koole R., Brandwijk R.J., Storm G., Chin P.T.K., Strijkers G.J., Donega C.D., Nicolay K., and Griffioen A.W. Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett. 6 (2006) 1-6
29. Reimer P., and Tombach B. Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur. Radiol. 8 (1998) 1198-1204
30. Zhang Z., Greenfield M.T., Spiller M., McMurry T.J., Lauffer R.B., and Caravan P. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew. Chem., Int. Ed. 44 (2005) 6766-6769
31. de Vries I.J.M., Lesterhuis W.J., Barentsz J.O., Verdijk P., van Krieken J.H., Boerman O.C., Oyen W.J.G., Bonenkamp J.J., Boezeman J.B., Adema G.J., Bulte J.W.M., Scheenen T.W.J., Punt C.J.A., Heerschap A., and Figdor C.G. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23 (2005) 1407-1413
32. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34 (1955) 1345-1353
33. Wasan K.M., Brocks D.R., Lee S.D., Sachs-Barrable K., and Thornton S.J. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat. Rev. Drug Discov. 7 (2008) 84-99
34. Nichols A.V., Krauss R.M., and Musliner T.A. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. 128 (1986) 417-431
35. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., and Kriegert M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 (1996) 518-520
36. Davidson W.S., Lund-Katz S., Johnson W.J., Anantharamaiah G.M., Palgunachari M.N., Segrest J.P., Rothblat G.H., and Phillips M.C. The influence of apolipoprotein structure on the efflux of cellular free cholesterol to high density lipoprotein. J. Biol. Chem. 269 (1994) 22,975-22,982
37. Rye K.-A., and Barter P.J. Antiinflammatory actions of HDL: a new insight. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1890-1891
38. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
39. Gordon D.J., and Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N. Engl. J. Med. 321 (1989) 1311-1316
40. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., and Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333 (1995) 1301-1307
41. Kontush A., Guerin M., and Chapman M.J. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat. Clin. Pract., Cardiovasc. Med. 5 (2008) 329-336
42. Geninatti Crich S., Lanzardo S., Alberti D., Belfiore S., Ciampa A., Giovenzana G.B., Lovazzano C., Pagliarin R., and Aime S. Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia 9 (2007) 1046-1056
43. Sinzinger H., Bergmann H., Kaliman J., and Angelberger P. Imaging of human atherosclerosis lesions using I-123 low-density-lipoprotein. Eur. J. Nucl. Med. 12 (1986) 291-292
44. Frias J.C., Williams K.J., Fisher E.A., and Fayad Z.A. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126 (2004) 16,316-16,317
45. Chen J., Corbin I.R., Li H., Cao W., Glickson J.D., and Zheng G. Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J. Am. Chem. Soc. 129 (2007) 5798-5799
46. McConathy W.J., Nair M.P., Paranjape S., Mooberry L., and Lacko A.G. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anti-cancer drugs 19 (2008) 183-188
47. Zheng G., Chen J., Li H., and Glickson J.D. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17,757-17,762
48. Shaish A., Keren G., Chouraqui P., Levkovitz H., and Harats D. Imaging of aortic atherosclerotic lesions by 125I-LDL, 125I-oxidized-LDL, 125I-HDL and 125I-BSA. Pathobiology 69 (2001) 225-229
49. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., and Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis through the arterial tree. Arterioscler. Thromb. 14 (1994) 133-140
50. Frias J.C., Ma Y., Williams K.J., Fayad Z.A., and Fisher E.A. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 6 (2006) 2220-2224
51. Jonas A. Reconstitution of high-density lipoproteins. Methods Enzymol. 128 (1986) 553-582
52. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J., Badimon J.J., Stefanadis C., Moreno P., Pasterkamp G., Fayad Z., Stone P.H., Waxman S., Raggi P., Madjid M., Zarrabi A., Burke A., Yuan C., Fitzgerald P.J., Siscovick D.S., de Korte C.L., Aikawa M., Airaksinen K.E.J., Assmann G., Becker C.R., Chesebro J.H., Farb A., Galis Z.S., Jackson C., Jang I.K., Koenig W., Lodder R.A., March K., Demirovic J., Navab M., Priori S.G., Rekhter M.D., Bahr R., Grundy S.M., Mehran R., Colombo A., Boerwinkle E., Ballantyne C., Insull W., Schwartz R.S., Vogel R., Serruys P.W., Hansson G.K., Faxon D.P., Kaul S., Drexler H., Greenland P., Muller J.E., Virmani R., Ridker P.M., Zipes D.P., Shah P.K., and Willerson J.T. From vulnerable plaque to vulnerable patient - a call for new definitions and risk assessment strategies: part I. Circulation 108 (2003) 1664-1672
53. Briley-Saebo K.C., Geninatti Crich S., Cormode D.P., Barazza A., Mulder W.J.M., Chen W., Giovenzana G.B., Fisher E.A., Aime S., and Fayad Z.A. High-relaxivity gadolinium-modified high-density lipoproteins as magnetic resonance imaging contrast agents. J. Phys. Chem. B 113 (2009) 6283-6289
54. Cormode D.P., Briley-Saebo K.C., Mulder W.J.M., Aguinaldo J.G.S., Barazza A., Ma Y., Fisher E.A., and Fayad Z.A. An apoA-I mimetic peptide HDL-based MRI contrast agent for atherosclerotic plaque composition detection. Small 4 (2008) 1437-1444
55. D.P. Cormode, R. Chandrasekar, A. Delshad, K.C. Briley-Saebo, C. Calcagno, A. Barazza, W.J.M. Mulder, E.A. Fisher, Z.A. Fayad, Comparison of synthetic HDL contrast agents for MR imaging of atherosclerosis, Bioconjugate Chem. 20 (2009) 937-943.
56. Chen W., Vucic E., Leupold E., Mulder W.J.M., Cormode D.P., Briley-Saebo K.C., Barazza A., Fisher E.A., Dathe M., and Fayad Z.A. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol. Imaging 3 (2008) 233-242
57. Sauer I., Nikolenko H., Keller S., Abu Ajaj K., Blenert M., and Dathe M. Dipalmitoylation of a cellular uptake-mediating apolipoprotein E-derived peptide as a promising modification for stable anchorage in liposomal drug carriers. Biochim. Biophys. Acta, Biomembr. 1758 (2006) 552-561
58. Rosen J.M., Butler S.P., Meinken G.E., Wang T.S.T., Ramakrishnan R., Srivastava S.C., Alderson P.O., and Ginsberg H.N. Indium-111-labeled LDL: a potential agent for imaging atherosclerotic disease and lipoprotein biodistribution. J. Nucl. Med. 31 (1990) 343-350
59. Pietzsch J., Bergmann R., Rode K., Hultsch C., Pawelke B., Wuest F., and van den Hoff J. Fluorine-18 radiolabeling of low-density lipoproteins: a potential approach for characterization and differentiation of metabolism of native and oxidized low-density lipoproteins in vivo. Nucl. Med. Biol. 31 (2004) 1043-1050
60. Ginsberg H.N., Goldsmith S.J., and Vallabajosula S. Noninvasive imaging of 99mTechnetium-labeled low density lipoprotein uptake by tendon xanthomas in hypercholesterolemic patients. Arteriosclerosis 10 (1990) 256-262
61. Corbin I.R., Li H., Chen J., Lund-Katz S., Zhou R., Glickson J.D., and Zheng G. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 8 (2006) 488-498
62. Mitsumori L.M., Ricks J.L., Rosenfeld M.E., Schmiedl U.P., and Yuan C. Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease. Int. J. Card. Imaging 20 (2004) 561-567
63. Li H., Gray B.D., Corbin I.R., Lebherz C., Choi H., Lund-Katz S., Wilson J.M., Glickson J.D., and Zhou R. MR and fluorescent imaging of low-density lipoprotein receptors. Acad. Radiol. 11 (2004) 1251-1259
64. Huettinger M., Corbett J.R., Schneider W.J., Willerson J.T., Brown M.S., and Goldstein J.L. Imaging of hepatic low-density lipoprotein receptors by radionuclide scintiscanning in vivo. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 7599-7603
65. Longino M.A., Bakan D.A., Weichert J.P., and Counsell R.E. Formulation of polyiodinated triglyceride analogues in a chylomicron remnant-like liver-selective delivery vehicle. Pharm. Res. 13 (1996) 875-879
66. Wisner E.R., Weichert J.P., Longino M.A., Counsell R.E., and Weisbrode S.E. A surface-modified chylomicron remnant-like emulsion for percutaneous computed tomography lymphography. Invest. Radiol. 37 (2002) 232-239
67. Douglas T., and Young M. Viruses: making friends with old foes. Science 312 (2006) 873-875
68. Suttle C.A. Viruses in the sea. Nature 437 (2005) 356-361
69. Johnson J., Lin T., and Lomonossoff G. Presentation of heterologous peptides on plant viruses: genetics, structure, and function. Annu. Rev. Phytopathol. 35 (1997) 67-86
70. Wellink J. Comovirus isolation and RNA extraction. In: Foster G.D., and Taylor S.C. (Eds). Plant Virology Protocols: From Virus Isolation to Transgene Resistance (1998), Humana Press, Totana, New Jersey 205-209
71. Ochoa W.F., Chatterji A., Lin T.W., and Johnson J.E. Generation and structural analysis of reactive empty particles derived from an icosahedral virus. Chem. Biol. 13 (2006) 771-778
72. Royston E., Lee S.-Y., Culver J.N., and Harris M.T. Characterization of silica-coated tobacco mosaic virus. J. Colloid Interface Sci. 298 (2006) 706-712
73. Dujardin E., Peet C., Stubbs G., Culver J.N., and Mann S. Organization of metallic nanoparticles using tobacco mosaic virus templates. Nano Lett. 3 (2003) 413-417
74. Nam K.T., Wartena R., Yoo P.J., Liau F.W., Lee Y.J., Chiang Y.-M., Hammond P.T., and Belcher A.M. Stamped microbattery electrodes based on self-assembled M13 viruses. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 17,227-17,231
75. Comellas-Aragones M., Engelkamp H., Claessen V.I., Sommerdijk N.A.J.M., Rowan A.E., Christianen P.C.M., Maan J.C., Verduin B.J.M., Cornelissen J.J.L.M., and Nolte R.J.M. A virus-based single-enzyme nanoreactor. Nat. Nano. 2 (2007) 635-639
76. Flenniken M.L., Liepold L.O., Crowley B.E., Willits D.A., Young M., and Douglas T. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem. Commun. (2005) 447-449
77. Huh Y.M., Lee E.S., Lee J.H., Jun Y.W., Kim P.H., Yun C.O., Kim J.H., Suh J.S., and Cheon J. Hybrid nanoparticles for magnetic resonance imaging of target-specific viral gene delivery. Adv. Mater. 19 (2007) 3109-3112
78. Allen M., Bulte J.W.M., Liepold L., Basu G., Zywicke H.A., Frank J.A., Young M., and Douglas T. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn. Reson. Med. 54 (2005) 807-812
79. Anderson E.A., Isaacman S., Peadbody D.S., Wang E.Y., Canary J.W., and Kirshenbaum K. Viral nanoparticles donning a paramagnetic coat: conjugation of MRI contrast agents to the MS2 capsid. Nano Lett. 6 (2006) 1160-1164
80. Datta A., Hooker J.M., Botta M., Francis M.B., Aime S., and Raymond K.N. High relaxivity gadolinium hydroxypyridonate viral capsid conjugates: nanosized MRI contrast agents. J. Am. Chem. Soc. 130 (2008) 2546-2552
81. Liepold L., Anderson S., Willits D.A., Oltrogge L., Frank J.A., Douglas T., and Young M. Viral capsids as MRI contrast agents. Magn. Reson. Med. 58 (2007) 871-879
82. Singh P., Prasuhn D., Yeh R.M., Destito G., Rae C.S., Osburn K., Finn M.G., and Manchester M. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J. Control. Release 120 (2007) 41-50
83. Suci P.A., Berglund D.L., Liepold L., Brumfield S., Pitts B., Davison W., Oltrogge L., Hoyt K.O., Codd S., Stewart P.S., Young M., and Douglas T. High-density targeting of a viral multifunctional nanoplatform to a pathogenic, biofilm-forming bacterium. Chem. Biol. 14 (2007) 387-398
84. Vasalatiy O., Gerard R.D., Zhao P., Sun X., and Sherry A.D. Labeling of adenovirus particles with PARACEST agents. Bioconjug. Chem. 19 (2008) 598-606
85. Hooker J.M., O'Neil J.P., Romanini D.W., Taylor S.E., and Francis M.B. Genome-free viral capsids as carriers for positron emission tomography radiolabels. Mol. Imaging Biol. 10 (2008) 182-191
86. Flexman J.A., Cross D.J., Lewellen B.L., Miyoshi S., Kim Y., and Minoshima S. Magnetically targeted viral envelopes: a PET investigation of initial biodistribution. IEEE Trans. Nanobiosci. 7 (2008) 223-232
87. Lewis J.D., Destito G., Zijlstra A., Gonzalez M.J., Quigley J.P., Manchester M., and Stuhlmann H. Viral nanoparticles as tools for intravital vascular imaging. Nat. Med. 12 (2006) 354-360
88. Chen C., Daniel M.-C., Quinkert Z.T., De M., Stein B., Bowman V.D., Chipman P.R., Rotello V.M., Kao C.C., and Dragnea B. Nanoparticle-templated assembly of viral protein cages. Nano Lett. 6 (2006) 611-615
89. Huang X., Bronstein L.M., Retrum J., DuFort C., Tsvetkova I., Aniagyei S., Stein B., Stucky G., McKenna B., Remmes N., Baxter D., Kao C.C., and Dragnea B. Self-assembled virus-like particles with magnetic cores. Nano Lett. 7 (2007) 2407-2416
90. Portney N.G., Singh K., Chaudhary S., Destito G., Schneemann A., Manchester M., and Ozkan M. Organic and inorganic nanoparticle hybrids. Langmuir 21 (2005) 2098-2103
91. Joo K.-I., Lei Y., Lee C.-H., Lo J., Xie J., Hamm-Alvarez S.F., and Wang P. Site-specific labeling of enveloped viruses with quantum dots for single virus tracking. ACS Nano 2 (2008) 1553-1562
92. Theil E.C. Ferritin: structure, gene regulation, and cellular function in animals, plants and microorganisms. Ann. Rev. Biochem. 56 (1987) 289-315
93. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., and Helpern J.A. Increased iron-related MRI contrast in the substantia-nigra in Parkinson's disease. Neurology 45 (1995) 1138-1143
94. Mani V., Briley-Saebo K.C., Hyafil F., and Fayad Z.A. Feasibility of in vivo identification of endogenous ferritin with positive contrast MRI in rabbit carotid crush injury using GRASP. Magn. Reson. Med. 56 (2006) 1096-1106
95. Genove G., DeMarco U., Xu H., Goins W.F., and Ahrens E.T. A new transgene reporter for in vivo magnetic resonance imaging. Nat. Med. 11 (2005) 450-454
96. Brooks R.A., Vymazal J., Goldfarb R.B., Bulte J.W.M., and Aisen P. Relaxometry and magnetometry of ferritin. Magn. Reson. Med. 40 (1998) 227-235
97. Goussin Y., Gillis P., Muller R.N., and Hocq A. Relaxation by clustered ferritin: a model for ferritin-induced relaxation in vivo. NMR Biomed. 20 (2007) 749-756
98. Bennett K.M., Shapiro E.M., Sotak C.H., and Koretsky A.P. Controlled aggregation of ferritin to modulate MRI relaxivity. Biophys. J. 95 (2008) 342-351
99. Wood J.C., Fassler J.D., and Meade T. Mimicking liver iron overload using liposomal ferritin preparations. Magn. Reson. Med. 51 (2004) 607-611
100. Uchida M., Terashima M., Cunningham C.H., Suzuki Y., Willits D.A., Willis A.F., Yang P.C., Tsao P.S., McConnell M.V., Young M.J., and Douglas T. A human ferritin iron oxide nano-composite magnetic resonance contrast agent. Magn. Reson. Med. 60 (2008) 1073-1081
101. Bennett K.M., Zhou H., Sumner J.P., Dodd S.J., Bouraoud N., Doi K., Star R.A., and Koretsky A.P. MRI of the basement membrane using charged nanoparticles as contrast agents. Magn. Reson. Med. 60 (2008) 564-574
102. Russo L.M., Sandoval R.M., McKee M., Osicka T.M., Collins A.B., Brown D., Molitoris B.A., and Comper W.D. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int. 71 (2007) 504-513
103. Hainfeld J.F. Uranium-loaded apoferrin with antibodies attached: molecular design for uranium neutron-capture therapy. Proc. Natl. Acad. Sci. 89 (1992) 11064-11064
104. Yang Z., Wang X., Diao H., Zhang J., Li H., Sun H., and Guo Z. Encapsulation of platinum anticancer drugs by apoferritin. Chem. Commun. (2007) 3453-3455
105. Hennequin B., Turyanska L., Ben T., Beltran A.M., Molina S.I., Li M., Mann S., Patane A., and Thomas N.R. Aqueous near-infrared fluorescent composites based on apoferritin-encapsulated PbS quantum dots. Adv. Mater. 20 (2008) 3592-3596
106. Aime S., Frullano L., and Geninatti Crich S. Compartmentalization of a gadolinium complex in the apoferritin cavity: a route to obtain high relaxivity contrast agents for magnetic resonance imaging. Angew. Chem., Int. Ed. 41 (2002) 1017-1019
107. Geninatti Crich S., Bussolati B., Tei L., Grange C., Esposito G., Lanzardo S., Camussi G., and Aime S. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res. 66 (2006) 9196-9201
108. Lorence R.M., Roberts M.S., O'Neil J.D., Groene W.S., Miller J.A., Mueller S.N., and Bamat M.K. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 7 (2007) 157-167
109. Carlisle R.C., Benjamin R., Briggs S.S., Sumner-Jones S., McIntosh J., Gill D., Hyde S., Nathwani A., Subr V., Ulbrich K., Seymour L.W., and Fisher K.D. Coating of adeno-associated virus with reactive polymers can ablate virus tropsim, enable retargeting and provide resistance to neutralising antisera. J. Gene Med. 10 (2008) 400-411